Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer.

Abstract The methods for treatment of advanced prostate cancer, based on the agonistic analogs of LH-RH were reviewed. New therapeutic approaches utilizing antagonistic analogs of LH-RH such as SB-75 (Cetrorelix) have been described. Analogs of LH-RH chemically linked to various cytotoxic radicals are also being developed. Combinations of LH-RH agonists or antagonists with superactive somatostatin analogues such as Octastatin (RC-160) or with borobesin/GRP antagonists are being investigated in order to delay or prevent the relapse and improve the therapy for prostate cancer. LH-RH / analogs / prostate cancer